Spring Pharmaceutical Group, Inc. (CYIG) financial statements (2020 and earlier)

Company profile

Business Address 11 QUANXING ROAD
SICHUI, 273200
State of Incorp. FL
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25108131930
Cash and cash equivalents25108131930
Receivables011000
Inventory, net of allowances, customer advances and progress billings252121
Inventory252121
Prepaid expense and other current assets0
Other undisclosed current assets22110 
Total current assets:301811152131
Noncurrent Assets
Property, plant and equipment17141313139
Intangible assets, net (including goodwill)121212151718
Intangible assets, net (excluding goodwill)121212151718
Other undisclosed noncurrent assets51454534170
Total noncurrent assets:807270624727
TOTAL ASSETS:1109081776759
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:000011
Taxes payable121211
Other undisclosed accounts payable and accrued liabilities(1)(2)(1)(1)  
Due to related parties 1    
Other liabilities    00
Other undisclosed current liabilities2212  
Total current liabilities:231211
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 2    
Total noncurrent liabilities: 2    
Total liabilities:251211
Stockholders' equity
Stockholders' equity attributable to parent, including:1058780756657
Preferred stock000000
Common stock000000
Additional paid in capital445444
Accumulated other comprehensive income (loss)4(4)1554
Retained earnings948575665849
Other undisclosed stockholders' equity attributable to parent22    
Stockholders' equity attributable to noncontrolling interest3     
Other undisclosed stockholders' equity (2)   (0)
Total stockholders' equity:1088580756657
TOTAL LIABILITIES AND EQUITY:1109081776759

Income statement (P&L) ($ in millions)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Revenues655648383433
Revenue, net 048 3433
Cost of revenue
(Cost of Goods and Services Sold)
(40)(33)(27)(20)(17)(17)
Other undisclosed gross profit   111
Gross profit:252321191817
Operating expenses(11)(10)(10)(8)(7)(8)
Operating income:15131112119
Nonoperating income (expense)
(Investment Income, Nonoperating)
 00(0)  
Other undisclosed income from continuing operations before equity method investments, income taxes1  008
Income from continuing operations before income taxes:161311121118
Income tax expense (benefit)(4)(3)33(3)(2)
Net income:12101415815
Net income attributable to noncontrolling interest 0    
Other undisclosed net loss attributable to parent  (6)(6)  
Net income attributable to parent:121089815
Other undisclosed net loss available to common stockholders, basic(0)     
Net income available to common stockholders, diluted:111089815

Comprehensive Income ($ in millions)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Net income:12101415815
Other undisclosed comprehensive income (loss)8(5)    
Comprehensive income:2051415815
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(1)0    
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(0)(10)(6)10
Comprehensive income, net of tax, attributable to parent:21559916

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: